# Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

> **NCT00066690** · PHASE3 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 3066 (actual)

## Conditions studied

- Estrogen Receptor Positive Breast Cancer
- Progesterone Receptor Positive Tumor
- Recurrent Breast Carcinoma
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer

## Interventions

- **DRUG:** Exemestane
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Oophorectomy
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **DRUG:** Tamoxifen
- **DRUG:** Triptorelin

## Key facts

- **NCT ID:** NCT00066690
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12-17
- **Primary completion:** 2014-05
- **Final completion:** 2024-11-06
- **Target enrollment:** 3066 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066690, "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00066690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*